Evolent Health revenue plunges 31% as one-time losses and debt maturities strain liquidity

Evolent Health, Inc. (EVH) - NYSE

Snapshot - what's happening inside
Evolent is navigating a major business mix shift and higher financing costs while continuing to run its value‑based specialty care platform. Revenue has fallen materially vs. 2024 because several large contracts were re-scoped or moved between product suites. Management says liquidity is sufficient for at least the next 12 months, but the company has taken on new secured term debt and recorded several one‑time, non‑operational charges this period.

Key points & statistics (facts from the 10‑Q)
* Revenue - Q2 2025: $444,328 (vs $647,145 Q2 2024); Six months 2025: $927,977 (vs $1,286,798) - declines of 31.3% (Q) and 27.9% (6M).
* Operating result - Q2 2025 operating loss: $(1,171); Six months operating loss: $(2,793).
* Net loss attributable to common shareholders - Q2: $(51,090); Six months: $(123,340).
* Loss per share - Q2: $(0.44); Six months: $(1.07). Weighted‑avg shares (6M): 115,600.
* Cash and restricted cash - Cash & cash equivalents $150,995; Restricted cash $26,975; total cash + restricted cash $177,970 (end of period).
* Accounts receivable, net - $358,756 (June 30, 2025).
* Reserve for claims & performance arrangements - $187,251 (down from $318,705 at 12/31/24).
* Intangibles & goodwill - Intangible assets, net $651,169; Goodwill $1,137,321.
* Debt & financing - Short‑term debt, net $172,119; Long‑term debt, net $648,455; Convertible notes principal outstanding: 2025 Notes $172,500 and 2029 Notes $402,500 (aggregate convertible notes $575,000 principal).
* Interest expense - $11,601 (Q2); $21,986 (6M).
* Large non‑operating hits - Loss on option exercise (purchase of equity interest) recorded ~ $52.5 million YTD; extinguishment of Series A Preferred Stock charge $9,000 (6M).
* Customer concentration - Q2 revenue mix: Molina Healthcare, Inc. 27.2%; Cook County Health 17.4%; Florida Blue Medicare 14.1%; Centene 11.9% - a few partners drive a large share of revenue.
* Liquidity stance - Management: "sufficient liquidity to meet working capital and capital expenditure requirements for at least the next twelve months."

Positive aspects (income statement & balance sheet)
* Strong cash position: $150.995M cash with total cash + restricted cash $177.97M - provides runway while management executes financing options.
* Lowered claim reserves: reserve for claims fell from $318.7M to $187.3M - indicates large claim payments settled (but also reflects contract scope changes).
* Cost of revenue fell in absolute terms ($343.9M vs $540.3M) and as a % of revenue (77.4% vs 83.5%) owing to a shift toward higher‑margin product mix.
* Management reduced amortization expense vs. prior year (depreciation & amortization down ~22% Q) after accelerated amortization of retired trade names in 2024.
* Enterprise scale intact: goodwill $1.137B and intangible asset base $651M support long‑term service platform value.

Negative aspects / risks (income statement & financials)
* Revenue deterioration: total revenue down ~31% year‑over‑year (Q) driven by contract transitions and scope narrowing - top‑line pressure is material and recurring until new wins ramp.
* Large net losses and negative EPS: Q2 net loss $(51.1M); 6M net loss $(123.3M); EPS -$1.07 (6M). Operating margins are under stress.
* Big one‑time and non‑cash charges: ~$52.5M loss on option exercise (purchase of JV interest), $9.0M extinguishment charge related to Series A amendments - these materially widen the reported loss.
* Rising financing cost and leverage: interest expense jumped (6M interest $21.99M) after new term loans; long‑term debt jumped and convertible note maturities (2025 note maturity Oct 15, 2025) create refinancing/repayment pressure.
* Short‑term liquidity & maturity risk: $172.5M 2025 convertible notes mature October 15, 2025 - company negotiated credit amendments and an Incremental Facility/Exchange with Ares; subsequent Exchange (Aug 7, 2025) converted Series A Preferred into a second‑lien term loan but that is a post‑period event and underscores balance‑sheet strain.
* Operating cash flow weak: operating cash used $(25.8M) YTD; investing used $(73.6M) YTD - company relied on financing ($98.9M provided) to cover outflows.
* Customer concentration: top partners account for a large portion of revenue (e.g., Molina 27.2% Q2) - loss/renegotiation of any major partner could be material.
* Credit / covenant risk: Credit Agreements impose liquidity and leverage covenants; defaults or inability to refinance could force asset sales or further dilution.

What to watch next (near‑term catalysts & risk areas)
* 2025 Notes maturity (Oct 15, 2025) and the company's actions to retire/replace that debt - financing outcome will materially affect leverage and interest costs.
* Collection and accounts receivable trends and the timing of claims payments (working capital volatility).
* New contract wins, go‑lives and how Performance Suite membership and PMPM fees trend - these drive revenue recovery and margin improvement.
* Any further large non‑operational charges (JV unwind, contingent consideration payments) that continue to depress GAAP earnings.
* Results from the One Big Beautiful Bill Act (tax law change) analysis and its impact on tax and deferred items (company evaluating impact).

Plain takeaway
Evolent is a scaled specialty/value‑based care operator facing a material revenue contraction this year due to contract re‑scopes and product‑mix shifts. The company still holds meaningful intangible and platform value and a cash cushion, but profitability is being eroded by large non‑recurring charges, higher interest expense and significant debt maturities. The next several months of financing activity (2025 note maturity handling, covenant compliance) and whether new business ramps will restore revenue are the decisive factors for near‑term investors.

Source: Evolent Health, Inc. Form 10‑Q for the quarter ended June 30, 2025 (figures quoted exactly as reported).